COVID-19 vaccines: Who might win the race to the global market?

Posted by Kristyn Feldman on Fri, May 15, 2020

Samaya Krishnan, Parul Rewari, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

Access COVID-19 resources

In the face of the COVID-19 pandemic, the world is racing to find a safe and effective vaccine for the SARS-CoV2 virus, and industry and academic researchers have initiated clinical trials across the world to test various candidates. In upcoming blogs, we will explore the different vaccine technologies in clinical development, along with where they originated and where they might be tested and manufactured.


>
Read More

Are we seeing a plateau in new entrants to the COVID-19 clinical pipeline?

Posted by Kristyn Feldman on Tue, May 05, 2020

Parul Rewari, Edwin Reyes, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

Access COVID-19 resources

We are closely watching the evolving clinical trial landscape for COVID-19, and each week the staggering volume of trials continues to increase. Last week, we saw the familiar addition of a large number of new trials1 but noticed that the number of unique assets2 may be plateauing: While many assets are adding additional trials across new geographies, the number of new entrants into the race to address the novel coronavirus may be slowing down (figure 1).


>
Read More

The COVID-19 pipeline: Introducing our weekly report and vaccine and treatment pipeline tracker

Posted by Kristyn Feldman on Fri, Apr 17, 2020

Parul Rewari, Amit Pangasa, Cody Powers and Judith Kulich co-wrote this blog post with Kristyn Feldman.

Access COVID-19 resources

Clinical development efforts continue to advance toward finding safe and effective treatments and vaccines for COVID-19. Each week, we are taking a look at the notable updates and results across the global community of academic and industry clinical trials. By the middle of the third week in April, there were more than 530 trials for COVID-19 listed on clinicaltrials.gov (figure 1).1 We have observed an incredible number of trials added each week, with a 75% increase in trial volume in April alone.1


>
Read More

The COVID-19 pipeline: An unprecedented global clinical development effort

Posted by Kristyn Feldman on Mon, Apr 06, 2020

Parul Rewari, Cody Powers, Judith Kulich and Amit Pangasa co-wrote this blog post with Kristyn Feldman.

The global COVID-19 pandemic continues to dominate headlines, including near constant updates from the pharma industry and academic clinical researchers the world over. Last week, we looked at the clinical-stage programs aimed to address the novel coronavirus. This week, we have expanded our analysis to include a wider range of clinical programs, including phase IV studies, and additional sources of data regarding this quickly evolving landscape.


>
Read More